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Streptococcus pneumoniae is the leading cause of bacterial pneumonia. Although this is a vaccine pre-
ventable disease, S. pneumoniae still causes over 1 million deaths per year, mainly in children under
the age of five. The biggest disease burden is in the developing world, which is mainly due to unavailabil-
ity of vaccines due to their high costs. Protein polysaccharide conjugate vaccines are given routinely in
the developed world to children to induce a protective antibody response against S. pneumoniae. One
of these vaccines is Prevnar13, which targets 13 of the 95 known capsular types. Current vaccine produc-
tion requires growth of large amounts of the 13 serotypes, and isolation of the capsular polysaccharide
that is then chemically coupled to a protein, such as the diphtheria toxoid CRM197, in a multistep expen-
sive procedure. In this study, we design, purify and produce novel recombinant pneumococcal protein
polysaccharide conjugate vaccines in Escherichia coli, which act as mini factories for the low-cost produc-
tion of conjugate vaccines. Recombinant vaccine efficacy was tested in a murine model of pneumococcal
pneumonia; ability to protect against invasive disease was compared to that of Prevnar13. This study pro-
vides the first proof of principle that protein polysaccharide conjugate vaccines produced in E. coli can be
used to prevent pneumococcal infection. Vaccines produced in this manner may provide a low-cost alter-
native to the current vaccine production methodology.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Streptococcus pneumoniae (the pneumococcus) is the leading
cause of bacterial pneumonia. The highest disease burden is
observed in the developing world due to limited vaccine availabil-
ity [1]. In the developed world, since the introduction of pneumo-
coccal conjugate vaccines, S. pneumoniae disease burden in
children has drastically reduced (PCV7/10/13) [2,3]. Prevnar7 was
the first pneumococcal conjugate vaccine produced and was intro-
duced in the UK in 2006. Post introduction, invasive pneumococcal
disease caused by vaccine serotypes dropped by 41% [2]. After
introduction of Prevnar13 (PCV13) in 2010 invasive disease caused
by the additional 6 serotypes dropped by 75% [4].PCV13 is a component of the childhood vaccine schedule in the
UK and is given to all children in a three-dose schedule at 2, 4 and
12 months of age. This vaccine targets the capsular polysaccharide
surrounding the bacteria. PCV13 protects against the 13 (out of 95)
pneumococcal serotypes found to be most prevalent in disease [5].
Polysaccharide alone is not immunogenic in children under 2 years
of age, and does not produce a lasting immune response [6]. Con-
jugate vaccines work by coupling the polysaccharide component to
a protein carrier [7], resulting in a protective T-cell dependent
memory response [8]. This technology was first used for the pro-
duction of a Haemophilus influenzae type B vaccine [9], followed
by conjugate vaccines to prevent Neisseria meningitidis serogroup
C [10], and subsequently pneumococcal infection [11]. Pneumococ-
cal conjugate vaccines are the world’s best-selling vaccines, and in
2014 PCV13 sales produced revenues of £2.9 billion [12].
Although these glycoconjugate vaccines are very effective, there
are some limitations to their use. Serotype distribution of disease
causing isolates varies geographically [13]. The PCV7 vaccine
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vaccine did not provide adequate protection against serotypes
prevalent in developing countries. However, the introduction of
an additional 6 serotypes in PCV13 includes the main disease-
causing serotypes in the developing world [5,13]. Serotype replace-
ment remains a problem, and introduction of vaccines has resulted
in increased incidence of disease from non-vaccine serotypes
[2,14,15]. The most recent emerging serotypes (22F and 33F) are
included in a new 15-valent vaccine preparation [16]. Finally, the
high cost of conjugate vaccines means they are often not available
to the poorest regions, which have the greatest disease burden.
The complex nature of the production process of the conjugate
vaccine is one contributing factor to the high cost. Using standard
methods, growth of large quantities of pathogenic pneumococci is
required for isolation of the polysaccharide. Post purification the
polysaccharide must then be chemically coupled to the carrier pro-
tein, in the case of PCV13 a diphtheria toxoid (CRM197). This pro-
cess is time consuming, requires several rounds of purification to
remove toxic chemicals and by products, and can often result in
batch to batch variation [17].
An increase in the understanding of bacterial protein glycosyla-
tion has led to development of novel ways to couple protein and
polysaccharide (reviewed in [18]). The approach, often referred
to as protein glycan coupling technology (PGCT) allows production
of protein polysaccharide conjugate vaccines in Escherichia coli
[19]. This technology utilises an oligosaccharyltransferase enzyme,
PglB, from the general protein glycosylation locus (Pgl) of Campy-
lobacter jejuni [19]. This locus encodes the genes required for the
production of a C. jejuni heptasaccharide along with PglB, which
is required for coupling of the heptasaccharide to a carrier protein.
PglB couples over sixty C. jejuni proteins to this heptasaccharide
[20]. These proteins contain an amino acid acceptor sequence,
which is recognised by PglB [21]. The consensus, or glycotag,
sequence can be engineered into any protein carrier, allowing
recognition by PglB [21]. The glycan specificity of C. jejuni PglB
has been well characterised, using this knowledge researchers
have been able to couple a number of different polysaccharides
to chosen carrier proteins using PglB [21–23]. In simple terms,
PGCT can be divided into three procedures. In the first stage, genes
encoding the target glycan are faithfully cloned and expressed in
E. coli on a suitable plasmid. In the second stage, the target carrier
protein containing the appropriate consensus sequon and purifica-
tion tag are cloned into a suitable plasmid, and targeted to the peri-
plasm. Finally, the coupling enzyme, CjPglB, recognises the initial
sugar on the glycan and transfers it to the carrier protein. The plas-
mids are introduced into an appropriate E. coli host strain to pro-
duce an inexhaustible supply of recombinant glycoprotein that
can be readily purified [19].
There are a number of vaccines that have been produced using
this technology that show excellent promise in both animal models
and in clinical trials [24–27]. Vaccines produced using PGCT will
reduce vaccine costs, speed up the production process, and negate
the need for growth of large volumes of pathogenic bacteria. Other
benefits of using this technology include the ability to readily
change the carrier protein, and to add further compatible polysac-
charide types. Further, this technology could allow rapid addition
of polysaccharides to vaccine preparations to protect against
emerging serotypes. Vaccines produced in this manner could also
be tailored to specific geographical regions, by protecting against
the most prevalent serotypes. To date pneumococcal polysaccha-
rides of type 4, 5, 8 and 12F have been expressed in E. coli [28],
the first stage of PGCT.
In the current study, we provide the first evidence that recom-
binant protein polysaccharide conjugate vaccines can be produced
in E. coli and protect against pneumococcal invasive disease in a
murine infection model.2. Materials and methods
2.1. Bacterial strains and plasmids
Escherichia coli strains were grown in modified super optimal
broth, SSOB (Tryptone 2%, Yeast extract 0.5%, NaCl 10 mM, KCl
2.5 mM, MgCl2 10 mM, MgSO4 10 mM) at 28 C, with shaking.
Antibiotics were added as necessary for plasmid maintenance:
tetracycline 20 mg ml1; ampicillin 100 mg ml1; chloramphenicol
30 mg ml1. A table of strains and plasmids used in this study can
be found in the supplementary information (Table S1).
Streptococcus pneumoniae strain (TIGR4) was cultured on BHI
agar with 5% horse blood, or statically in BHI broth, in an atmo-
sphere containing 5% CO2.2.2. Vaccine production
Recombinant serotype 4 polysaccharide was produced in E. coli,
as previously described [28]. Conjugation to AcrA was carried out
using protein glycan coupling technology [25]. E. coli cultures were
grown for 16 h. These starter cultures were used to inoculate 2 L of
SSOB to an OD600 of 0.03 and incubated with shaking at 28 C.
Once OD600 had reached 0.4–0.6, expression of PglB was induced
with the addition of 1 mM IPTG. MnCl2 was also added to a final
concentration of 4 mM. After 20 h growth at 28 C cells were pel-
leted by centrifugation at 5400g for 30 min at 4 C. Pellets were
resuspended in lysis buffer (50 mM NaH2PO4, 0.3 M NaCl and 10
mM imidazole, pH 7.5) with 1 mg/ml lysozyme, and lysed using
a FastPrep instrument (MP Biomedicals) with lysing matrix B.
Supernatant was treated with 250 units benzonase for 10 min.
Insoluble debris was removed by centrifugation at 7800g for 60
min at 4 C and the supernatant passed through a 0.2 mm filter.
The protein/polysaccharide conjugate labeled with a polyhistidine
affinity tag was purified using HisTrap columns (GE Healthcare)
using an imidazole gradient of 20–300 mM on an AKTA protein
purification system (GE Healthcare).2.3. SDS-PAGE and immuno blot analysis
To verify glycoconjugate production and to select AKTA frac-
tions for pooling, samples were subject to SDS-PAGE followed by
coomassie staining or immunoblot. Rabbit anti-serotype 4 capsule
antibody from the Statens Serum Institut, (SSI) Denmark was used
at a dilution of 1:1000 and mouse anti-His monoclonal antibody
(Abcam, UK) was used at a dilution of 1:10,000 to detect recombi-
nant serotype 4 capsule and His-tagged AcrA respectively. HR6
antiserum was used to detect the Campylobacter heptasaccharide
(S. Amber and M. Aebi, unpublished data). Secondary goat anti-
rabbit IgG IRDye 800 and goat anti-mouse IgG IRDye 680 conju-
gates were used at a dilution of 1: 10 000. Fluorescent signal was
detected using an Odyssey LI-COR detection system (LI-COR Bio-
sciences UK Ltd.).2.4. Protein and polysaccharide (PS) quantification in vaccine
preparations
Selected AKTA fractions were concentrated using Vivaspin pro-
tein concentrator spin columns with 10 KDa MWCO (GE Health-
care) and protein was quantified using a Qubit protein assay
(Thermo Fisher Scientific). Levels of Type 4 polysaccharide in vac-
cine preparations was quantified by ELISA using type 4 antiserum
and a standard curve generated using purified type 4 polysaccha-
ride (SSI, Denmark).
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All in vivo experiments were carried out in accordance with the
UK Animal Scientific Procedures Act (1986). Mice used in this study
were 6–8 week old outbred female MF1 (Harlan, UK). Mice had
food and water ad libitum, were kept at a constant room temper-
ature of 20–22 C, with a 12 h light/dark cycle. For immunization,
each mouse received three subcutaneous injections with an
interval of two weeks between each. All vaccines were made up
in phosphate buffered saline (PBS). For the positive controls mice
were vaccinated with pneumococcal 13-valent conjugate vaccine
(PCV) Prevnar (Pfizer). Two dosing regimes were used for the
Prevnar control groups: PCV13 high vaccination contained 0.5 lg
of type 4 PS/dose, while PCV13 low contained 0.0001 lg type
4 PS/dose. The AcrA-SP4 conjugate vaccine contained 0.0001 lg
type 4 PS/dose. The AcrA alone and AcrA-Pgl vaccines were
normalised to contain the same amount of AcrA to that in the
AcrA-SP4 preparation. This was done by western blotting using
an anti-His tag antibody (Abcam, UK). Alhydrogel was added to
the experimental vaccine preparations to the same level as that
found in the PCV13 high dose (Type 4 PS only controls, AcrA only,
AcrA-Pgl, AcrA-SP4). Sham vaccination consisted of PBS with
Alhydrogel.2.6. Intranasal infection model
Four weeks after the last vaccinationmice were challenged with
S. pneumoniae serotype 4 strain, TIGR4. Mice were inoculated intra-
nasally with 5  106 colony forming units (CFU) in 50 ll PBS. All
mice were monitored for symptoms and were sacrificed at a desig-
nated clinical endpoint point. Organs were removed (lungs, liver,
spleen, brain), blood taken and viable counts performed using
the Miles and Misra method [29]. Mice that did not reach the clin-
ical endpoint were sacrificed at 7 days post infection and processed
in the same way. Blood samples from tail veins, body weight and
clinical scores were also taken throughout the study. Graphical
representation and statistical analysis was performed in Prism ver-
sion 4.0b (GraphPad Software), using a non-parametric Mann-
Whitney two sample rank test; significance P < 0.05. Survival of
mice receiving different vaccine preparations was compared using
a Kaplan-Meier survival curve and analysed using a Log-rank Test
(P < 0.05).2.7. Preparation of Luminex beads
Protein (AcrA) and polysaccharide (type 4 polysaccharide) were
coupled to carboxylate microspheres specific for use in the Lumi-
nex multiplex machine as described previously [30,31]. Briefly,
type 4 pneumococcal polysaccharide (SSI 5 mg/ml) was coupled
to poly-L-lysine (PLL) using cyanuric chloride. Type 4 PS coupled
to PLL was then purified using a G25 PD-10 Sephadex column
(GE healthcare). Type 4 PS-PLL was then coupled to carboxylated
microspheres (Bio-Plex COOH bead 11, BIO-RAD, UK). AcrA was
coupled to a different bead set (Bio-Plex COOH bead 47) at a con-
centration of 50 lg/ml and did not require prior coupling to PLL.
Coupling of beads to antigens was performed using standard meth-
ods. Briefly, beads were activated with 5 mg/ml EDC (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride) solution and
5 mg/ml NHS (N-hydroxysuccinimide) solution. Bead sets were
washed with PBS and incubated with their individual antigen. After
incubation, beads were washed in PBS and resuspended in 300 ll
PBS 0.1% BSA, 0.05% sodium azide and kept at 4 C in the dark until
used.2.8. Luminex assay antibody quantification
Assays were adapted from [31]. Briefly, sera taken from individ-
ual vaccinated mice prior to bacterial challenge were assessed for
antibodies against AcrA and type 4 polysaccharide. Serum was
diluted 1/100 in sample buffer (PBS 0.05% tween 20, 1% BSA, 5
lg/ml CWPS, 5 lg/ml 22F PS). A standard curve was created from
serial 10 fold dilutions of a human standard serum (0 0 7). This
serum has known anti-pneumococcal PS antibody titres and
allowed extrapolation of anti-type 4 PS antibody levels in mouse
sera from the human serum standard curve. For AcrA, antibody
levels are based on the mean fluorescent intensity values and are
relative quantifications of anti-AcrA antibodies between the differ-
ent vaccinated groups.
Assays were run in 96-well filter plates (Millipore, UK) with
2500 beads/antigen in each well. To each well 25 ll of diluted sera
was added. A type 4 antiserum and a PCV13 mouse control sera
were run as internal controls for anti-type 4 PS antibodies for each
assay. An in house anti-AcrA antibody was used as an internal con-
trol for AcrA samples. Beads and sera were incubated at room tem-
perature for 1 h with shaking at 500 rpm. Beads were washed with
PBS 0.05% tween 20 then incubated with a 1/200 dilution of anti-
human, anti-rabbit or anti-mouse IgG phycoerythrin (PE) conju-
gate antibody (Southern Biotech, UK) for 30 min, shaking at 500
rpm. Beads were washed 2 as above and resuspended in 125 ll
PBS 0.05% tween 20. Data was acquired on a Luminex-100 instru-
ment (BIO-RAD, UK). Data analysis was performed on Bio-Plex
manager 4.1.1 software, which created the standard curve from
the 007 human sera. From this anti-type 4 PS, antibody levels in
mouse sera were extrapolated. Graphical representation was per-
formed in Prism version 4.0b (GraphPad Software) showing anti-
body titres in the different vaccinated groups. Statistical analysis
was performed using a Kruskal-Wallis one-way ANOVA with a
Dunn’s multiple comparison test (P < 0.05).
2.9. Opsonophagocytic killing assay (OPKA)
HL60 cells were maintained in RPMI medium 1640 GlutaMAX
(Thermofisher, UK) supplemented with 20% fetal calf serum, 1
penicillin streptomycin and 2 mM L-glutamine. Differentiation
was performed using a cell density of 4  105 cells/ml in 0.8%
Dimethylformamide. Cells were differentiated for 5 days and then
used in the OPKA. Cells were washed in HBSS/+ Ca2+/Mg2+ and
resuspended at the desired concentration in opsonisation buffer
(OPB buffer) (1 ml 10 HBSS+ Ca2+/Mg2+,1 ml gelatin, 530 ll Fetal
bovine serum, 8 ml H2O).
OPKAs were performed on serum samples taken from vacci-
nated mice. Serum was heat inactivated for 30 min at 56 C. Serial
two-fold dilutions of sera were performed in PBS with a starting
dilution of 1:2. TIGR4 was added to each well at a concentration
of 2.5  103 cfu and incubated for 30 min at 4 C. Bacteria were
pelleted by centrifugation and 15% baby rabbit complement was
added, followed by 5  105 differentiated HL60 cells. Following
incubation at 37 C in 5% C02 for 40 min, the contents of each well
were diluted 1/10 in PBS, and the dilution and neat samples plated
onto BAB plates containing 5% horse blood. Plates were incubated
overnight at 37 C in 5% CO2. Colonies were counted and percent-
age killing calculated in comparison to the bacteria, complement
and cells only control (no sera added). Type 4 antiserum (SSI)
and an in house PCV13 mouse control serum were used as internal
controls. Graphical representation was performed in Prism version
4.0b (GraphPad Software) showing percentage killing of TIGR4
with sera from vaccinated mice relative to the bacteria, comple-
ment and HL60 cells only control.
Fig. 1. Recombinant glycoconjugate vaccine preparations produced in E. coli. 0.5 mg protein separated on SDS-PAGE gel for batch 1 (A/B) and batch 2 (C/D), A/C – Immunoblot
with anti-His tag antibody (red) and anti- SP4 capsule antibody (green). SP4 antiserum cross reacts with AcrA. B/D – Coomassie stained gel. A/B. Lane 1: AcrA conjugated to
recombinant SP4 polysaccharide. C/D Lane 1: AcrA only; lane 2: AcrA conjugated to C. jejuni heptasaccharide; lane 3: AcrA conjugated to recombinant SP4 polysaccharide. M:
molecular weight marker PageRuler Plus. i = unglycosylated AcrA, ii = AcrA glycosylated with single glycan unit at one glycosylation site, iii = AcrA glycosylated with single
glycan unit at both glycosylation sites, iv = AcrA glycosylated with polymerized SP4 at one glycosylation site, v = AcrA glycosylated with polymerized SP4 at both
glycosylation sites. Images have been cropped for clarity and ease of labelling. Each sub figure contains lanes cropped from the same gel. Separate, uncropped figures for each
of the fluorescence channels are presented in supplementary data (Fig. S2 and S3). (For interpretation of the references to colour in this figure legend, the reader is referred to
the web version of this article.)
Table 1
Comparison of SP4-AcrA P1 and P2.
SP4-AcrA P1 SP4-AcrA P2
Yield per g of cells 201 lg 180 lg
% glycosylated AcrA 80% 84%
AcrA attached to polymer 3.6% 2.8%
AcrA per dose of vaccine 26.8 lg 15.9 lg
3812 J.A. Herbert et al. / Vaccine 36 (2018) 3809–3819The datasets generated during and/or analysed during the cur-
rent study are available from the corresponding author on reason-
able request.
3. Results
3.1. Coupling of serotype 4 pneumococcal polysaccharide to AcrA
The oligosaccharyltransferase, CjPglB, was used to transfer
recombinantly expressed S. pneumoniae serotype 4 capsular
polysaccharide to AcrA. CjPglB covalently attaches glycans to
asparagine residues, within a conserved motif, via an N-
glycosidic bond [32,21]. The pglB gene was introduced onto the
chromosome of E. coli wild type strain W3110, to form strain
W311B (Abouelhadid et al. manuscript in preparation). Previous
work has shown that S. pneumoniae serotype 4 capsular polysac-
charide can be recombinantly expressed in E. coli using the plas-
mid, pB-4 [28]. AcrA is a protein that forms part of a multidrug
efflux pump in C. jejuni [33], and is known to be glycosylated with
a heptasaccharide via PglB in vivo [19]. AcrA has also been used as a
glycan carrier in a conjugate vaccine produced against brucellosis
[34]. In this study, E. coli strain W311B was transformed with plas-
mids pB-4 (carrying the serotype 4 capsule locus) and pWA2
(carrying acrA) to generate a glycoconjugate vaccine consisting of
AcrA coupled to type 4 polysaccharide. Control strains were also
generated by transformation of W311B: with pWA2 only, to
express AcrA; or in combination with pPgl (pACYC carrying thewhole pgl locus from C. jejuni with pglB mutated) to conjugate
the C. jejuni heptasaccharide to AcrA. Following overnight induc-
tion with IPTG, cells were lysed and the AcrA protein was purified
by affinity chromatography. 0.5 mg of protein purified from each
recombinant strain was analysed by SDS-PAGE and immunoblot-
ting (Fig. 1). When AcrA alone is expressed, a single band of 40
KDa is visualized with the anti-His tag antibody (Lane 1 in
Fig. 1C). AcrA conjugated to the C. jejuni heptasaccharide has three
his-reactive bands, with the most abundant band being the high-
est, corresponding to AcrA glycosylated at both sites with the C.
jejuni heptasaccharide, which does not form a polymer (Lane 2 in
Fig. 1C). Yield of conjugate vaccine was low (Table 1: 201 lg and
180 lg per g wet-weight of E. coli, for AcrA-SP4 P1 and P2 respec-
tively) and therefore two separate batches of vaccine were purified
for mouse vaccination and protection studies (Fig. 1: Panel A1 and
C3). In the AcrA-SP4 samples, three bands react with the anti-His
tag antibody. One of these three bands has the same molecular
weight as AcrA and is therefore predicted to be non-glycosylated
AcrA. The two higher molecular weight bands represent AcrA gly-
cosylated at one and two glycosylation sites. A further group of
bands at higher molecular weights can be seen above the protein,
representing polymer chains attached at one and two sites.3.2. In vivo vaccine efficacy
To assess the protective efficacy of the recombinant glycoconju-
gate vaccine containing type 4 polysaccharide coupled to AcrA
(AcrA-SP4), mice were vaccinated with conjugates followed by
challenge with S. pneumoniae strain TIGR4. Type 4 polysaccharide
was chosen to test the conjugation approach because the unconju-
gated polysaccharide is not immunogenic in mice [35]. This
allowed us to test the immunogenicity of the conjugate alone as
no protection would be observed from any free polysaccharide pre-
sent in the vaccine preparations [35].
The amount of type 4 PS in the vaccine preparation was mea-
sured using ELISA against a type 4 PS standard serum from SSI
J.A. Herbert et al. / Vaccine 36 (2018) 3809–3819 3813(data not shown). The quantity of AcrA in the preparations was
measured by western blot using a HIS-tag antibody, and the
amount of AcrA normalised between the AcrA containing prepara-
tions (data not shown). PCV13 was used as a positive control and
the amount of type 4 polysaccharide in PCV13 was matched to that
in the AcrA-SP4 conjugate (0.0001 lg). This was designated as Pre-
vnar low dose (PLD) due to the relatively low amount of type 4
polysaccharide in AcrA-SP4. A higher dose of PCV13 (PHD) was alsoFig. 2. Bacterial counts in Blood, Brain and Lungs. Fig. 2A shows Levels of bacteria in the b
Bacteria in the blood is shown at 24 h post challenge (taken via tail vein bleed) and at time
analysis was performed on data, n = 3 mice/group. Fig. 2B shows levels of bacteria in the b
vein bleed) and at the TOD. Red circular symbol represents data from the mouse that
performed in GraphPad Prism using a non-parametric Mann-Whitney two sample rank
single animal.given as a positive control, as our previous studies showed this was
protective in our mouse model of infection (containing 0.5 lg type
4 polysaccharide/dose).
Two separate batches of the experimental conjugate were
tested.
MF1 outbred mice were vaccinated with three doses of: AcrA-
SP4, Prevnar13 (PHD/PHL) or one of the control groups (unconju-
gated type 4 PS (high/low dose), AcrA alone, AcrA coupled to itslood, lungs and brain of vaccinated mice (preparation 1) post challenge with TIGR4.
of death (TOD, taken via cardiac puncture under terminal anesthesia). No statistical
lood of vaccinated mice (preparation 1 and 2) at 24 h post challenge with TIGR4 (tail
was vaccinated with AcrA-SP4 P2 and survived challenge. Statistical analysis was
test, significance *P < 0.05, n = 3–5 mice/group. Each dot represents counts from a
Fig. 3. Survival of vaccinated mice post intranasal challenge with TIGR4. This figure
shows survival of vaccinated mice following challenge with TIGR4. Mice were
followed for disease progression, once clinical symptoms reached a designated
endpoint mice were sacrificed. Experimental endpoint was 7 days post challenge
(168 h) and surviving mice were sacrificed at this time point. n = 5 mice/group bar
AcrA-SP4 P1 where n = 3 and AcrA-SP4 P2 where n = 4. Statistical analysis was
performed in GraphPad Prism using a Log-rank Test (P < 0.05).
3814 J.A. Herbert et al. / Vaccine 36 (2018) 3809–3819native C. jejuni heptasaccharide (AcrA-Pgl) or sham vaccinated).
Four weeks post the last vaccination mice were challenged via
the intranasal route with a serotype 4 S. pneumoniae strain (TIGR4).
Disease progression was assessed in all vaccinated groups.
Initial experiments used three mice to test the first vaccine
preparation, referred to as AcrA-SP4 P1. Small groups of mice were
used due to amounts of conjugate required for the vaccination
schedule. Further experiments were performed using a second
batch of conjugate vaccine, referred to as AcrA-SP4 P2 (n = 4). Data
is presented separately for the two groups due to the differing
results observed for the two preparations.
In the initial experiment, using Preparation 1 of the AcrA-SP4
vaccine, three mice were vaccinated for each group. All mice in
the PHD vaccinated group survived the infection, whereas all mice
in the PLD group succumbed. The experimental AcrA-SP4 conju-
gate vaccine conferred 100% protection. Analysis of bacterial
counts in the lungs, brain and blood showed no bacteria present
above the limit of detection in the organs of mice vaccinated with
PHD or AcrA-SP4 P1 (Fig. 2A). Due to the low numbers of mice, sta-
tistical analysis was not performed.
Next we attempted to repeat these experiments with a second
batch of AcrA-SP4 conjugate (AcrA-SP4 P2). However, in this series
of experiments only one mouse from the group of 4 vaccinated,Fig. 4. Antibody responces in vaccinated mice. A shows the IgG antibody responces to th
the IgG antibody responces to type 4 polysaccharide in vaccinated mice, measured usin
with TIGR4. Each dot represent antibody levels in a single animal. Red circular symbol in
survived challenge. Statistical analysis was performed in GraphPad Prism using a Kruskal-
***P < 0.001. (For interpretation of the references to colour in this figure legend, the reasurvived bacterial challenge. The surviving mouse showed no bac-
terial counts in the blood at 24 h and at the time of death (Fig. 2B).
Whereas, the three mice that succumbed to infection all had bac-
teria in the blood at 24 h post infection, similar to that observed
in the control groups. The PHD positive control group was pro-
tected from infection and showed significantly lower (P < 0.05)
bacterial counts in the blood compared to all control groups
(except AcrA-SP4, analysis was performed on all AcrA-SP4 vacci-
nated mice together (n = 7)), data not shown on graph. Mice vacci-
nated with AcrA-SP4 P1 had significantly lower bacterial counts in
the blood at both time points compared to the T4PS high/low, AcrA,
AcrA-Pgl and sham vaccinated control groups. This was not
observed with mice vaccinated with AcrA-SP4 P2.
Survival curves were used to compare the two preparations
(Fig. 3). Mice vaccinated with AcrA-SP4 P1 showed a 100% survival
rate (n = 3), whereas mice vaccinated with AcrA-SP4 P2 only had a
25% survival rate (n = 4). Despite a trend towards a difference there
was no significant difference between survival rates with mice vac-
cinated with AcrA-SP4 P1 and P2 (P 0.0798). No significant differ-
ence was observed between PHD and AcrA-SP4 P1 vaccinated mice.
Further, all control groups (sham, T4PS high/low, AcrA and AcrA-
Pgl) showed a significant reduction in survival compared to mice
vaccinated with AcrA-SP4 P1. No significant difference in survival
was observed between control groups (sham, T4PS high/low, AcrA
and AcrA-Pgl) and mice vaccinated with AcrA-SP4 P2.
Using Western blot analysis, the two AcrA-SP4 vaccine prepara-
tions were compared using fluorescent intensity measurements
(supplementary Fig. 1). As the SSI SP4 antiserum cross-reacts with
AcrA all measurements were confined to the anti-his channel. This
analysis revealed a higher percentage glycosylation for AcrA-SP4
P2 (84% Vs 80%) but a lower percentage of AcrA coupled to poly-
mers of SP4 (2.8% Vs 3.6%). In addition, by normalizing to glycan
content of the preparations, the protein content per dose of the
P1 was 26.8 lg vs 15.9 lg in P2 (Table 1 and supplementary Fig. 1).
In an attempt to explain the variation in levels of protection of
the two vaccine preparations, we examined the antibody levels and
functionality of the antibodies generated by the two vaccines.3.3. Vaccine induced antibody responses
A Luminex bead based assay was used to evaluate the amount
of antibody produced against type 4 PS and the carrier proteine carrier protein AcrA in vaccinated mice, measured using a luminex assay. B shows
g a Luminex assay. Antibody responces were measured in sera taken pre challenge
dicates the antibody levels in the mouse that was vaccinated with AcrA-SP4 P2 and
Wallis one way ANOVAwith a Dunn’s multiple comparison test, *P < 0.05, **P < 0.01,
der is referred to the web version of this article.)
J.A. Herbert et al. / Vaccine 36 (2018) 3809–3819 3815AcrA, in serum from vaccinated mice (Fig. 4). Sera used were
obtained from tail vein bleeds taken directly before challenge with
TIGR4. Type 4 PS levels are given in lg/ml as samples were com-
pared to a standard human serum with known levels of anti-type
4 PS antibody (lg/ml) [36]. AcrA levels are presented as relativeFig. 5. Functional antibody levels in vaccinated mice. (A) shows functional antibodies in
line represents sera from a single mouse. Percentage killing of TIGR4 is shown at dilutio
seven mice vaccinated with AcrA-SP4 P1 and AcrA-SP4 P2. Each line represents sera from
intranasal infection, and open square those that succumbed to infection. Red filled square
second vaccine preparation group. (C) shows functional antibodies in sera from a singl
dilutions of sera starting at 1:2 dilution. (For interpretation of the references to colour iamounts of IgG between the different samples, as no serum stan-
dard with known levels of AcrA antibody was available.
Anti-AcrA antibodies were detected in all serum samples taken
from mice that were vaccinated with AcrA conjugates (AcrA-SP4/
AcrA-Pgl) or AcrA alone (Fig. 4A). The AcrA-SP4 vaccinated micesera from mice vaccinated with AcrA-SP4 P1 (blue), PHD (red) and PLD (black). Each
ns of sera starting at 1:2 dilution. (B) shows functional antibodies in sera from all
a single mouse with the circular symbol representing the mice that survived TIGR4
symbol indicated the functional antibody levels in the mouse that survived from the
e mouse from each of the control groups. Percentage killing of TIGR4 is shown at
n this figure legend, the reader is referred to the web version of this article.)
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with the first (AcrA-SP4 P1 n = 3) and second preparation (AcrA-
SP4 P2 n = 4). The antibody titer from the mouse that was vacci-
nated with the second preparation and survived is shown by a
red circular symbol. There was no significant difference in the
levels of anti-AcrA antibodies in AcrA vaccinated groups, suggest-
ing this is not the cause of the difference in survival.
Anti-type 4 PS antibody levels in vaccinated groups are shown in
Fig. 4B. The AcrA-SP4 vaccinated mice antibody responses have
been split into those that were vaccinated with the first (AcrA-
SP4 P1 n = 3) and second preparation (AcrA-SP4 P2 n = 4). Anti-
type 4 PS antibody levels were detectable in the PHD vaccinated
mice and AcrA-SP4 vaccinatedmice. Therewas no significant differ-
ence in antibody levels between the PHD group and the two AcrA-
SP4 groups (analysis was performed on all AcrA-SP4 vaccinated
mice together (n = 7)). There were significantly lower levels of
anti-type 4 PS antibodies in the PLD vaccinated group compared
to PHD high (P = <0.001) and the AcrA-SP4 vaccinated group (n =
7, P = <0.01), suggesting the lower PCV13 dose is not sufficient to
produce detectable levels of anti-type 4 PS antibodies in our model.
When splitting the AcrA-SP4 vaccinated mice into the two prepara-
tions there was no significant difference in the anti-type 4 PS levels
between the AcrA-SP4mice vaccinated with the first or second vac-
cine preparation. This suggests that the mice that succumbed to
infection did have anti-type 4 PS antibodies, but these were not suf-
ficient to clear infection. We know from previous literature [35]
that unconjugated type 4 PS is not immunogenic in mice, and this
is confirmed in our model as no anti-type 4 PS antibodies were
detected in the polysaccharide only control groups.
WHO has assigned a protective IgG serotype specific antibody
level of 0.35 lg/ml as measured by ELISA [37]. However, it has
been shown that this does not necessarily correlate with protec-
tion; OPKA is seen to be a better measure of true protection
[38,39]. There was no significant difference in the total anti-type
4 PS IgG antibody levels in mice vaccinated with the first or second
AcrA-SP4 vaccine preparation. Therefore, the ability of the antibod-
ies to opsonise TIGR4 was tested using an OPKA. Dilutions of sera
from single vaccinated mice were incubated with TIGR4, differen-
tiated HL-60 cells, and a complement source. Percentage killing of
TIGR4, when incubated with sera from vaccinated mice, was com-
pared to samples that contained no sera (bacteria, cells and com-
plement only control). In our assay, all sera that resulted in
bacterial killing above 50% is classed as protective. This assay
was then used to test functional antibodies in the sera from mice
vaccinated with AcrA-SP4.
Initial experiments were performed on sera frommice given the
first vaccine preparation. Sera samples taken from vaccinated mice
were tested individually. Samples were run alongside a standard
type 4 PS antisera (SSI) to assess any intra-assay variability (data
not shown). This assay confirmed whether antibodies produced
from vaccination of mice were able to opsonise and kill TIGR4
in vitro, which has been shown to correlate with protection [40].
Data in Fig. 5A shows the percentage killing of TIGR4 from the
three vaccinated mice with AcrA-SP4 P1, PHD and PLD. All mice
vaccinated with PHD and AcrA-SP4 P1 showed opsonic antibodies
above the 50% killing cut off. The three mice vaccinated with the
PLD did not show this and all mice in this group succumbed to
infection.
This assay was then used to test the opsonic antibody levels in
the mice vaccinated with AcrA-SP4 P2, and compared to the AcrA-
SP4 P1 data (Fig. 5B). One serum sample taken from a mouse in
each of the control groups was also tested (Fig. 5C). From our OPKA
data, we observe functional antibodies (killing above 50%) in all
sera samples from mice that survived intranasal challenge with
TIGR4. In the seven mice that received AcrA-SP4, functional anti-
bodies were observed in the four mice that survived; this wasnot the case for the three mice that succumbed to infection. Sera
from mice that were sacrificed due to clinical disease symptoms
did not reach killing above the 50% threshold. Data from the mouse
that was vaccinated with the AcrA-SP4 P2 but survived challenge is
shown as a red square symbol (Fig. 5B). We observed high levels of
killing in the sera from one of the PCV13 low vaccinated mice,
which survived challenge (data not shown). For the other control
groups, percentage killing did not reach above 50%; again, this cor-
related to the survival status of the mouse. There is therefore a
strong correlation between the ability of the antisera to promote
opsonophagocytosis in vitro and the ability to protect from infec-
tion in vivo.4. Discussion
We report the first demonstration of the use of protein glycan
coupling technology (PGCT) to produce a recombinant pneumococ-
cal conjugate vaccine candidate. We have provided the first proof
of principle that a recombinant pneumococcal conjugate vaccine
can be protective in a mouse model of infection, and can produce
functional opsonic antibodies. Production of these opsonic anti-
capsular antibodies correlates with the ability to protect from
lethal infection in a mouse model of disease.
Glycoconjugate vaccines are used worldwide to prevent disease
in children caused by encapsulated bacteria. In the UK, conjugate
vaccines are given in the routine childhood vaccination schedule
to prevent disease from three important pathogens: H. influenza
type B, N. meningitides, and S. pneumoniae. These vaccines are all
composed of type specific polysaccharide coupled to a carrier pro-
tein, normally diphtheria toxoid or tetanus toxoid. Despite large
reductions in disease caused by these pathogens since conjugate
vaccine introduction, these pathogens still remain the three big-
gest contributors to invasive disease in children worldwide
[1,41,42]. Conjugate vaccines that protect against pneumococcal
infection are known for their safety and efficacy. Producing protec-
tive type specific opsonic antibodies [5]. However pneumococcal
pneumonia remains one of the biggest killers, resulting in
393,000 deaths of children under 5 in 2015 [43].
This is mainly due to the limited availability of these vaccines in
the developing world, due to the large cost [12]. Introduction of
conjugate vaccines into a countries vaccine schedules is extremely
costly. Many developing countries are only able to afford these vac-
cines with assistance from The Global Vaccine Alliance (GAVI),
which is not sustainable. If eligibility for financial help is lost this
leaves a huge financial gap to fill.
PGCT is an alternative approach to making conjugate vaccines.
Producing conjugate vaccines in E. coli without the need for com-
plex chemical coupling, and growth of large quantities of patho-
genic bacteria. Once optimised, this production method has the
potential to significantly reduce the cost of conjugate vaccines,
making them more readily available globally. This production
method will not help with the problem of serotype replacement,
but an easier production method may allow more rapid switching
of vaccine constituents, to include compatible emerging serotypes
into the preparation.
This technology has recently been used for production of a
number of novel vaccines. These include vaccines that protect
against Francisella tularensis, Burkholderia pseudomellia and Staphy-
lococcus aureus [24–26]. These all used the CjPglB enzyme to cou-
ple O-antigen (gram negative bacteria) or type specific
polysaccharide (gram positive bacteria) to a carrier protein of
choice, in this instance to exotoxin A from Pseudomonas aeuriginosa
(F. tularensis and S. aureus) or AcrA from C. jejuni (B. pseudomellia).
These glycoconjugate vaccines produced using recombinant DNA
approaches all showed at least partial protection in a mouse model
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ponents. This methodology has also been used for production of
a glycoconjugate vaccine to prevent disease caused by Shigella flex-
neri 2a [27], coupling the O-antigen to exotoxin A (P. aeuriginosa)
using PglB. This conjugate vaccine composition produced through
chemical coupling has already been shown to be protective and
safe in clinical trials [44], however remains expensive to produce.
Using two separately prepared batches of vaccine, we observed
a 100% and 25% survival rate of mice vaccinated with AcrA-SP4
compared to 25% of mice vaccinated with the equivalent dose of
Prevnar13 (same concentration of type 4 PS – 0.0001 lg). Higher
survival rates of 100% were observed with the higher Prevnar13
dose, which is equal to each mouse receiving 100 ml of the neat
PCV13 vaccine per dose. Based on the PCV13 vaccine dose, and
weight of a 6 week old child, we have estimated a matched dose
for a mouse would contain 0.01 mg of type 4 PS/dose. This dosage
of 0.01 mg type 4 PS, when used in our infection model, was 100%
protective (data not shown). However, due to small amount of
AcrA-SP4 conjugate available we were unable to match these
doses, and each mouse received 0.0001 mg of type 4 PS per dose.
We believe the amount of AcrA-SP4 conjugate given to each
mouse was on the cusp of the amount required to protect against
challenge, and different vaccine efficacies observed to the two vac-
cine preparations is likely due to batch-to-batch variation. Optimi-
sation therefore is required to ensure a uniform batch, stability
post purification and the ability to scale up production.
The variation between batches may be due to reduced amounts
of coupled protein and polysaccharide present within the second
preparation. Total polysaccharide (type 4 PS) was quantified in
the vaccine preparations, and this was used to normalise doses
between the two experiments. However, this would not tell us if
the levels of protein and polysaccharide coupled varied between
preparations. To try and evaluate this the two vaccine preparations
were coupled to a Luminex assay bead set. The coupling method
used was for protein, so only the AcrA in the preparations would
bind to the beads. To measure the amount of AcrA coupled to
SP4, a secondary type 4 antisera was used (SSI) to quantify the
amount of T4PS coupled to the beads, followed by a PE conjugated
antibody (data not shown). Fluorescence readings were higher for
preparation one, indicating this preparation contained higher
amounts of AcrA coupled to T4PS. Type 4 polysaccharide alone is
not protective in a mouse model of infection [35]. Therefore, if
the level of free polysaccharide was higher in the second prepara-
tion this might account for the decrease in protection.
Another possibility for the reduced efficacy in the second prepa-
ration could be the composition of repeat unit lengths. It has been
shown previously that for S. pneumoniae serotype 4 glycoconju-
gates, a shorter chain lengths (12 repeat units), and a higher ratio
of saccharide to protein is required for optimal immunogenicity,
than for fully polymerized glycan [35]. Also, for serotype 14 the
length of coupled polysaccharide is important for induction of anti-
bodies with high opsonophagocytic activity; higher chain lengths
confirm higher opsonophagocytic titres [45]. However, this has
not been shown for other serotypes tested [46].
Relative amounts of IgG against AcrA were measured in all vac-
cinated mice. This carrier protein is not a native pneumococcal
protein and therefore provided no protection to mice. This was
clearly shown in the AcrA only and AcrA-Pgl vaccinated mice,
which all had anti-AcrA IgG antibodies in sera, yet all mice suc-
cumbed to infection. This was further validated using our OPKA,
as sera from vaccinated mice, in these two groups, were unable
to opsonise and kill TIGR4. A benefit of using PGCT, is that alterna-
tive protein carriers, that contribute to vaccine efficacy, could be
easily incorporated into vaccine preparations. One potential candi-
date to act as a carrier protein is pneumolysin (Ply), the pneumo-
coccal cholesterol dependent cytolysin. This protein is highlyconserved in almost all pneumococcal strains and serotypes [47].
Further, a detoxified version of ply (D6ply) has been shown to
act as an adjuvant, and upon vaccination, results in antibodies pro-
duced against itself and any proteins coupled to it [48,49]. These
properties are retained if given mucosally, and would enable the
vaccine to be given intranasally [49], a less invasive route than Pre-
vnar13 is currently given (intramuscularly).
Total IgG levels against T4PS in mice vaccinated with AcrA-SP4
did not seem to correlate to survival in our model. When the AcrA-
SP4 vaccinated groups were split into those that survived and
those that died post challenge with TIGR4, there was no significant
difference in antibody levels. For certain serotypes, total IgG levels,
as measured by ELISA, have been shown not to correlate with pro-
tection, and opsonic antibody activity has been shown to be a more
reliable measure of protection [38,39]. This was also the case in
this study, with opsonic antibody activity directly correlating to
survival.
In future, it may be informative to study antibody isotypes.
Pneumococcal conjugate vaccines have been shown to produce a
predominant IgG1 followed by IgG3 antibody response in mice
[35]. Response to polysaccharide alone manifest in a predomi-
nantly IgG2 and IgM response [35,50]. Increased levels of IgM or
IgG2 in mice vaccinated with the second preparation would have
supported the theory of increased free polysaccharide within this
preparation.
There are some limitations to overcome before this methodol-
ogy can compete with traditional chemical coupling. Currently
the use of the CjPglB is limited to coupling polysaccharides which
have an acetamido group at the C2 position of the reducing end
sugar [22]. This only includes a small number of the pneumococcal
polysaccharides. Work is underway to overcome these limitations.
CjPglB is not only found in campylobacter species, and orthologues
have also been found in a number of other epsilon proteobacteria
[51]. This opens up the potential to find glycosyltransferases that
have differing or relaxed glycan specificities to that of CjPglB. More
recently the crystal structure of PglB from Campylobacter lari has
been solved giving an insight into the important structural regions
required for PglB function [52]. With this knowledge, it is possible
to modify PglB to increase transfer efficiency and alter the glycan
specificity [53].
5. Conclusions
Here we have provided the first proof of principle that a pneu-
mococcal conjugate vaccine, produced by protein glycan coupling
technology, is protective in a mouse model of infection, and can
produce functional opsonic antibodies. A 57% survival rate of mice
vaccinated with the novel conjugate was seen, although there was
variation between vaccine preparations. This is a proof of principle
study and more work needs to be done to optimise production
methodology, to improve polymer length, conjugation efficiency
and overall vaccine yield, in order to make a reliable and econom-
ical alternative to chemical conjugation methods.
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